Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gain Therapeutics (GANX) Share-based Compensation (2020 - 2025)

Gain Therapeutics (GANX) has 6 years of Share-based Compensation data on record, last reported at $460005.0 in Q3 2025.

  • For Q3 2025, Share-based Compensation rose 28.67% year-over-year to $460005.0; the TTM value through Sep 2025 reached -$438878.0, down 116.97%, while the annual FY2024 figure was $190424.0, 94.16% down from the prior year.
  • Share-based Compensation reached $460005.0 in Q3 2025 per GANX's latest filing, down from $522019.0 in the prior quarter.
  • Across five years, Share-based Compensation topped out at $1.5 million in Q2 2024 and bottomed at -$1.8 million in Q4 2024.
  • Average Share-based Compensation over 5 years is $379933.7, with a median of $357505.0 recorded in 2024.
  • Peak YoY movement for Share-based Compensation: surged 333.48% in 2023, then crashed 431.57% in 2024.
  • A 5-year view of Share-based Compensation shows it stood at $286260.0 in 2021, then soared by 95.17% to $558692.0 in 2022, then decreased by 0.65% to $555059.0 in 2023, then plummeted by 431.57% to -$1.8 million in 2024, then skyrocketed by 124.99% to $460005.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Share-based Compensation were $460005.0 in Q3 2025, $522019.0 in Q2 2025, and $419504.0 in Q1 2025.